We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+21.97%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.76B
AUM Growth
+$163M
Cap. Flow
-$58.5M
Cap. Flow %
-2.12%
Top 10 Hldgs %
29.44%
Holding
155
New
9
Increased
52
Reduced
20
Closed
11

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$21.9M
2
EHC icon
Encompass Health
EHC
+$17.3M
3
ALLK
Allakos
ALLK
+$16.6M
4
ELAN icon
Elanco Animal Health
ELAN
+$13.2M
5
ENTA icon
Enanta Pharmaceuticals
ENTA
+$9.27M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$26.1M
2
GILD icon
Gilead Sciences
GILD
+$25.9M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$24.1M
4
ACHC icon
Acadia Healthcare
ACHC
+$22.1M
5
NUVA
NuVasive, Inc.
NUVA
+$19.4M

Sector Composition

Rank Sector Weight
1 Healthcare 89.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNH icon
1
UnitedHealth
UNH
$382B
$157M 5.67%
589,098
+21,598
+4% +$5.62M
ISRG icon
2
Intuitive Surgical
ISRG
$127B
$81.2M 2.94%
424,200
-1,500
-0.4% -$266K
MOH icon
3
Molina Healthcare
MOH
$10.4B
$81M 2.93%
545,000
– –
NBIX icon
4
Neurocrine Biosciences
NBIX
$18.2B
$79.3M 2.87%
645,000
+14,600
+2% +$1.66M
WCG
5
DELISTED
Wellcare Health Plans, Inc.
WCG
$75.5M 2.73%
235,500
+12,500
+6% +$3.55M
MDGL icon
6
Madrigal Pharmaceuticals
MDGL
$12.6B
$73.2M 2.65%
342,000
-300
-0.1% -$75.3K
AMRN
7
Amarin Corp
AMRN
$297M
$70.4M 2.55%
216,250
+16,250
+8% +$1.23M
GWPH
8
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$69.1M 2.5%
400,000
-40,000
-9% -$5.77M
PCRX icon
9
Pacira BioSciences
PCRX
$1.04B
$63.5M 2.3%
1,292,479
+94,479
+8% +$4.08M
HCA icon
10
HCA Healthcare
HCA
$90.6B
$63.3M 2.29%
455,000
+25,000
+6% +$3.11M
EHC icon
11
Encompass Health
EHC
$11.3B
$52.7M 1.91%
850,361
+284,711
+50% +$17.3M
SRPT icon
12
Sarepta Therapeutics
SRPT
$1.64B
$50.1M 1.82%
310,500
+13,000
+4% +$1.78M
IRTC icon
13
iRhythm Holdings
IRTC
$4.02B
$45.4M 1.65%
480,000
– –
ALXN
14
DELISTED
Alexion Pharmaceuticals
ALXN
$41.7M 1.51%
300,000
-192,500
-39% -$24.1M
VRTX icon
15
Vertex Pharmaceuticals
VRTX
$123B
$37.8M 1.37%
196,000
+5,500
+3% +$979K
ONC
16
BeOne Medicines Ltd
ONC
$33.9B
$37M 1.34%
215,000
– –
PEN icon
17
Penumbra
PEN
$12.6B
$35.2M 1.27%
235,200
-1,550
-0.7% -$217K
LOXO
18
DELISTED
Loxo Oncology, Inc
LOXO
$34.7M 1.26%
202,981
-86,919
-30% -$14.6M
TFX icon
19
Teleflex
TFX
$5.96B
$33M 1.19%
124,000
+31,500
+34% +$8.17M
CELG
20
DELISTED
Celgene Corp
CELG
$32.3M 1.17%
360,400
– –
SYK icon
21
Stryker
SYK
$135B
$31.8M 1.15%
179,000
+1,000
+0.6% +$171K
PRAH
22
DELISTED
PRA Health Sciences, Inc.
PRAH
$31.8M 1.15%
288,247
– –
EW icon
23
Edwards Lifesciences
EW
$49.4B
$31.3M 1.13%
540,000
+45,000
+9% +$2.2M
BSX icon
24
Boston Scientific
BSX
$68.4B
$30.8M 1.12%
800,000
+627,500
+364% +$21.9M
INGN icon
25
Inogen
INGN
$174M
$30.8M 1.11%
126,000
+7,000
+6% +$1.62M
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
ISS
Intesa Sanpaolo SpA. Turin, Italy $1.69B AUM
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

Rock Springs Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Rock Springs Capital Management held 155 positions worth $2.76B, up 6.3% from $2.6B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management's Q3 2018 filing shows 9 new, 52 increased, 20 reduced and 11 closed positions. Its largest new stake was Allakos: 405,000 shares worth $18.2M. The largest sale was AbbVie, an estimated $26.1M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 89% a quarter earlier.

  • Rock Springs Capital Management's largest Q3 2018 buy was Allakos: 405,000 shares worth $18.2M.
  • Rock Springs Capital Management added most to Boston Scientific in Q3 2018, an estimated $21.9M increase.
  • Rock Springs Capital Management's biggest Q3 2018 reduction was AbbVie, cutting an estimated $26.1M.
  • Rock Springs Capital Management fully exited Gilead Sciences in Q3 2018, selling an estimated $25.9M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $2.76B portfolio in Q3 2018.
  • Rock Springs Capital Management opened 9 new positions and closed 11 in Q3 2018.
  • Rock Springs Capital Management's portfolio value rose 6.3% quarter-over-quarter to $2.76B.

Based on Rock Springs Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.